COMP <GO>
CRSP vs ABBV // EV/EBITDA & P/E VALUATION
CRISPR Therapeutics AG (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CRSP 3
— ABBV 11
■ METRIC PARITY
LAST: $51.42 (-5.23%) • MKT CAP: $5.25B
valuation
—
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | 29.00% | -59.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | 3.47% | -10.06 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 8.60% | -73.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.97 | 5.33 | +2.64 | CRSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.40% | -0.10 | CRSP | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.6 | 72.8 | -25.18 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.15 | -0.03 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 113.1x | -85.10 | CRSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.25B | $513.86B | -$508.61B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | ABBV REV | CRSP GROSS % | ABBV GROSS % | CRSP FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $61.16B | 44.0% | 70.2% | -$345.9M | $17.82B |
| FY 2024 | $37.3M | $56.33B | 44.0% | 70.0% | -$144.7M | $17.83B |
| FY 2023 | $371.2M | $54.32B | 44.0% | 44.0% | -$277.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
ABBV // BETA 1.15